Produktbild
David (Hrsg.) Duggan

Oncogenomics

Molecular Approaches to Cancer

Ebook (PDF Format)

Diagnoses termed cancer consist of hundreds of different diseases with as many constellations of genetic alterations. Genomic technologies have made it possible to identify all of the tumor-specific mutations, to profile individual tumors at the DNA, RNA, and protein levels, and to test in cellular and animal systems the responses of particular genotypes to particular drugs. Oncogenomics and allied disciplines have identified new targets for genotype-specific treatments and provided strategies to validate these targets and to develop drugs. With the potential need to stratify patients by genotype, clinical testing of targeted drugs has become… Mehr

CHF 97.00

Preise inkl. MwSt. und Versandkosten (Portofrei ab CHF 40.00)

Versandfertig innerhalb 1-3 Werktagen
Versandkostenfrei

Produktdetails


Weitere Autoren: Brenner, Charles (Hrsg.)
  • ISBN: 978-0-471-47664-1
  • EAN: 9780471476641
  • Produktnummer: 13836843
  • Verlag: Wiley
  • Sprache: Englisch
  • Erscheinungsjahr: 2004
  • Seitenangabe: 400 S.
  • Plattform: PDF
  • Masse: 11'135 KB

Über den Autor


Charles Brenner is Director of the Cancer Mechanisms Program at Dartmouth's Norris Cotton Cancer Center in New Hampshire. He trained in yeast molecular biology with Anthony Brake at Chiron and yeast genetics with Kunihiro Matsumoto at DNAX before earning his Ph.D. in the biochemistry department at Stanford with Robert Fuller. In 1993, as a Leukemia Society Fellow, Brenner moved to Brandeis to train in X-ray crystallography with Gregory Petsko and Dagmar Ringe and then took an independent position at the Kimmel Cancer Center at Jefferson in 1996. Brenner rose to head the KCC's Program in Structural Biology and Bioinformatics in 2000 and joined Dartmouth Medical School's faculties of Genetics and Biochemistry in 2003. Dr. Brenner's research group uses genetics, enzymology and X-ray crystallography to dissect the cellular pathways perturbed by loss of the FHIT tumor suppressor gene, which is lost early in the development of many tumors of epithelial origin. David Duggan received his Ph.D. in 1997 in Human Genetics at Pittsburgh and trained with Jeffrey Trent in microarray analysis of breast and prostate cancer from 1998 to 2000 at the National Human Genome Research Institute. Duggan then served as an associate investigator at the National Institute of Arthritis and Musculoskeletal and Skin Diseases until 2003 when he took his current position at the Translational Genomics Research Institute in Arizona. Dr. Duggan's laboratory uses SNP genotyping and microarray analysis to investigate the genetic basis of human diseases.

1 weiteres Werk von David (Hrsg.) Duggan:


Bewertungen


0 von 0 Bewertungen

Geben Sie eine Bewertung ab!

Teilen Sie Ihre Erfahrungen mit dem Produkt mit anderen Kunden.